Study of L19IL2/TNF for advanced basal cell carcinoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination drug (L19IL2/TNF) given as injections into skin tumors. It is for people with advanced basal cell carcinoma that has worsened after or cannot tolerate standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced basal cell cancer that can be injected and measured.
- Your cancer has progressed on or you cannot take hedgehog inhibitors and anti-PD1 treatments.
- You are 18 years or older.
- You are able to do daily activities with some help (ECOG score 2 or less).
- You have adequate organ function on blood tests (hemoglobin, platelets, liver enzymes).
- You do not have other active cancers, serious infections, or heart problems as defined in the full list.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, L19IL2 and L19TNF, injected directly into advanced basal cell carcinoma tumors that cannot be treated with surgery or radiation. The goal is to see if these drugs can shrink the tumors.
This trial tests a combination of two drugs, L19IL2 and L19TNF, which are injected directly into skin tumors. It is for patients with advanced cutaneous squamous cell carcinoma that has not responded to or cannot tolerate immune checkpoint inhibitor therapy.
This trial tests a new cell therapy that uses your own immune cells (TILs) to fight lung cancer. If you have advanced non-small cell lung cancer and standard treatments haven't worked, this treatment might help your immune system attack the cancer more effectively.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.
Hear when a new Locally Advanced Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.